Scholar Rock Holding (SRRK) Assets Average (2018 - 2026)
Scholar Rock Holding's (SRRK) quarterly Assets Average came in at $469.8 million in Q1 2026, up 6.46% year-on-year from $441.2 million in Q1 2025, and up 15.14% quarter-over-quarter from $408.0 million in Q4 2025.
Scholar Rock Holding (SRRK) Assets Average (2018 - 2026) Analysis & Trends
Scholar Rock Holding's Assets Average history runs 9 years deep, the most recent figure standing at $469.8 million for Q1 2026.
- On a quarterly basis, Assets Average rose 6.46% year-over-year to $469.8 million in Q1 2026; TTM through Mar 2026 was $469.8 million, a 6.46% increase from a year earlier, with the FY2025 full-year figure at $439.6 million, up 11.86% from the prior year.
- Assets Average rose to $469.8 million in Q1 2026 per SRRK's latest filing, from $408.0 million in the prior quarter.
- Across five years, Assets Average topped out at $469.8 million in Q1 2026 and bottomed at $203.0 million in Q3 2024.
- The 5-year median for Assets Average is $336.4 million (2023), against an average of $337.2 million.
- Across the five-year window, Assets Average sank 34.24% in 2023 and surged 85.16% in 2025, its largest moves.
- Year by year, Assets Average stood at $374.2 million in 2022, then dropped by 24.95% to $280.9 million in 2023, then increased by 16.44% to $327.0 million in 2024, then climbed by 24.76% to $408.0 million in 2025, then rose by 15.14% to $469.8 million in 2026.
- Per Business Quant, the three latest SRRK Assets Average figures stand at $469.8 million (Q1 2026), $408.0 million (Q4 2025), and $375.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 303.40 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 65.01 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.37 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 41.64 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.06 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.71 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 795.91 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.30 Bn |
| 10 | Scholar Rock Holding | 6.30 Bn | 6.30 Bn | - | 469.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 469.76 Mn |
| Dec 31, 2025 | 408.00 Mn |
| Sep 30, 2025 | 375.88 Mn |
| Jun 30, 2025 | 373.80 Mn |
| Mar 31, 2025 | 441.24 Mn |
| Dec 31, 2024 | 327.03 Mn |
| Sep 30, 2024 | 203.00 Mn |
| Jun 30, 2024 | 247.08 Mn |
| Mar 31, 2024 | 289.16 Mn |
| Dec 31, 2023 | 280.86 Mn |
| Sep 30, 2023 | 267.79 Mn |
| Jun 30, 2023 | 299.81 Mn |
| Mar 31, 2023 | 336.44 Mn |
| Dec 31, 2022 | 374.24 Mn |
| Sep 30, 2022 | 407.22 Mn |
| Jun 30, 2022 | 345.05 Mn |
| Mar 31, 2022 | 285.21 Mn |
| Dec 31, 2021 | 301.42 Mn |
| Sep 30, 2021 | 315.22 Mn |
| Jun 30, 2021 | 346.32 Mn |